Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0L1GD
|
|||
Drug Name |
MK-8353
|
|||
Synonyms |
KPQQGHGDBBJGFA-QNGWXLTQSA-N; GTPL9974; SCHEMBL10236331; MK8353; (3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide
Click to Show/Hide
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | |
Company |
Merck Kenilworth, NJ
|
|||
Structure |
Download2D MOL |
|||
Formula |
C37H41N9O3S
|
|||
Canonical SMILES |
CC(C)OC1=NC=C(C=C1)C2=NNC3=C2C=C(C=C3)NC(=O)C4(CCN(C4)CC(=O)N5CCC(=CC5)C6=CC=C(C=C6)C7=NN(C=N7)C)SC
|
|||
InChI |
1S/C37H41N9O3S/c1-24(2)49-32-12-9-28(20-38-32)34-30-19-29(10-11-31(30)41-42-34)40-36(48)37(50-4)15-18-45(22-37)21-33(47)46-16-13-26(14-17-46)25-5-7-27(8-6-25)35-39-23-44(3)43-35/h5-13,19-20,23-24H,14-18,21-22H2,1-4H3,(H,40,48)(H,41,42)/t37-/m0/s1
|
|||
InChIKey |
KPQQGHGDBBJGFA-QNGWXLTQSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Ephrin type-B receptor 2 (EPHB2) | Target Info | Inhibitor | [1] |
KEGG Pathway | Axon guidance | |||
Panther Pathway | Angiogenesis | |||
Pathway Interaction Database | EPHB forward signaling | |||
EphrinB-EPHB pathway | ||||
Syndecan-2-mediated signaling events | ||||
Ephrin B reverse signaling | ||||
Reactome | EPH-Ephrin signaling | |||
L1CAM interactions | ||||
EPHB-mediated forward signaling | ||||
EPH-ephrin mediated repulsion of cells | ||||
WikiPathways | Transcriptional activation by NRF2 | |||
NLR Proteins | ||||
Regulation of Microtubule Cytoskeleton | ||||
L1CAM interactions |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.